[Localization of point mutations in the coding part of the VHL gene in clear cell renal cancer]

Area of Science:

• Oncogenetics
• Molecular Biology
• Cancer Research

Background:

• The VHL gene is frequently inactivated in clear cell renal cancer (CCRC), either through somatic mutations in sporadic cases or germline mutations in von Hippel-Lindau syndrome.
• Understanding VHL mutation patterns is critical for CCRC progression and targeted therapy sensitivity.

Purpose of the Study:

• To search for and characterize VHL gene mutations in primary CCRC.
• To identify novel mutations and analyze their impact on CCRC progression and treatment response.

Main Methods:

• Screening of 248 primary CCRC samples using Single-Strand Conformation Polymorphism (SSCP) analysis and DNA sequencing.
• Bioinformatic analysis of new missense mutations using alignment programs and 3D structure modeling.
• Comparison of mutation frequency across different patient groups based on stage, grade, and metastasis.

Main Results:

• Somatic VHL mutations were detected in 37.5% of CCRC samples, with 72% of these being novel.
• Early-stage (Stage I) CCRC showed a mutation frequency of 39.1%, but no significant association with tumor progression or metastasis was found.
• Analysis focused on the localization of mutations within critical VHL sequences, including missense mutations and in-frame deletions/insertions.

Conclusions:

• The study identified numerous novel VHL mutations in CCRC.
• VHL mutation analysis significantly improves laboratory diagnostics for both familial and sporadic CCRC.